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Objective. To evaluate fracture incidence, eﬀects on health-related quality of life(QoL), back pain (BP) occurrence and treatment
complianceinGreekpost-menopausalosteoporoticwomentreatedwithteriparatide(TPTD)forupto18months,inanaturalistic
setting.Methods.301patientsprovidedbaselineinformationondemographiccharacteristics,fracturehistory,osteoporosis-related
medication and risk factors. During treatment, QoL and BP severity were evaluated. Results. Mean (SD) age was 69.5 (±8.5) years.
Fracture history was reported by 92.5% of patients. Incidence of fractures (per 10,000 patients/years) ranged from 402 during 0–6
months of treatment, to 346 during 12–18 months. All 5 dimensions of QoL showed improvement. At baseline and 18 months, BP
was reported by 93.2% and 64.2% of patients, respectively. BP and limitation of activities were quantiﬁed as moderate or severe
by 89.9% and 62.3% of patients at baseline versus 32.4% and 14.8% at 18 months. Patients on treatment at 6, 12, 17, and 18
months were 92.6%, 88.3%, 79.6%, and 36.5%, respectively. Conclusions. In the Greek EFOS study cohort, patients prescribed
TPTD were severely osteoporotic, with considerable health-related problems. Signiﬁcant improvements in QoL and BP together
with low fracture rates and high compliance have been recorded during treatment.
1.Introduction
Fractures, whether vertebral or nonvertebral, symptomatic
or radiographically identiﬁed, is the most important com-
plication of postmenopausal osteoporosis. They are etio-
logically associated with increased mortality and morbidity,
chronicbackpain,andadeteriorationofhealth-relatedqual-
ityoflife(HRQoL)inwomenwithosteoporosis [1–5].These
fractures present a social-economic burden since approx-
imately 9 million osteoporotic fractures per year occur
globally, most of which are observed in postmenopausal
women [6]. The cost for their treatment in Europe alone is
estimated to exceed 76 billion Euros by 2050 [7].
Today, aminobisphosphonates are the most commonly
prescribed medications for the treatment of osteoporosis. By
suppressing bone resorption (antiresorptive medications),
they reduce the risk of new osteoporotic vertebral frac-
tures, while some, like alendronate, have shown signiﬁcant
reduction of nonvertebral fractures as well [8]. Recently,
anabolic antiosteoporotic agents were introduced, which, by
enhancing the bone formation, increase bone mass, improve
bone microarchitecture, enhance bone tolerance, and reduce
osteoporotic fractures [9, 10]. Teriparatide (TPTD), an
anabolic agent, is the recombinant (1–34) N-terminal of
human parathyroid hormone (PTH1−34). In a double-blind,
placebo-controlled clinical study, a 19-month TPTD treat-
mentreducedvertebralandnonvertebralfracturesinwomen
with severe osteoporosis [10]. Furthermore, it has been iden-
tiﬁed that TPTD treatment increases bone mineral density
(BMD) and reduces the risk of new osteoporotic fractures
to a greater extent than that observed with alendronate2 Journal of Osteoporosis
in patients (men or women) with glucocorticoid-induced
osteoporosis [11].
Ultimately, double-blind, randomized studies are the
cornerstone for the conﬁrmation of the eﬀectiveness of any
medication. However, their design and strict patient inclu-
sion and exclusion criteria limit their potential to provide
answersto questions concerning the “typical” patient in real-
life clinical practice. In a recent study, it was estimated that
from 120 patients with osteoporosis, 80% would not be
enrolled in a double-blind, randomized study, due to comor-
bidity or/and their osteoporotic or other concomitant med-
ication history [12]. Observational studies bridge that gap
and complement double-blind studies, providing answers to
a wide variety of clinical questions that emerge in everyday
clinical practice.
In the European Forsteo Observational Study (EFOS),
in contrast to clinical trials, all patients initiating TPTD in
a naturalistic setting were enrolled in a 3-year prospective,
noninterventional, multicenter design [13]. The results of 18
months of treatment with TPTD in the total cohort enrolled
in the study have been reported [14]. The present analysis
focuses on the subset of patients enrolled in Greece.
301 postmenopausal women with established osteoporo-
sis from 31 investigative sites in Greece enrolled in the
study with a total study period of 36 months (18-month
TPTD treatment period and 18-month period of followup).
Women enrolled in the EFOS study suﬀered from severe
osteoporosis accompanied by serious problems in mobility
and usual activities and experienced intense back pain,
anxiety, depression, and diminished health-related quality
of life [15]. The current analysis focuses on the results of
18-month TPTD treatment in terms of incidence of new
osteoporotic fractures, back pain, health-related quality of
life and compliance to treatment.
2.MaterialandMethods
The study design, patient demographics and the disease-
related data at baseline have been published elsewhere
[13, 15]. EFOS, as a noninterventional study, included all
postmenopausal women initiating TPTD in normal clinical
practice. The study only excluded patients who were treated
with any investigational drug or procedure at study entry, or
presented with one of the known contraindications for the
use of TPTD, as indicated in the compound’s SPC. Patients
signed an informed consent form to permit medical data
to be collected. Each patient could withdraw her consent
for participation in the study and leave the study without
consequence. The study was conducted according to Good
Clinical Practice, and Ethical Review Board permission was
given for all participating investigational sites.
At baseline, patient demographics, osteoporosis and
falls-related risk factors, antiosteoporotic medication(s)
already received, and the current disease state were recorded.
Following the initial visit, four prospective visits were con-
ducted at 3, 6, 12, and 18 months of TPTD treatment.
During these visits, patient compliance with treatment was
determined from the number of TPTD doses the patient
recalled missing in the month preceding the visit. New cli-
nical vertebral and nonvertebral fractures were diagnosed
and veriﬁed by an X-ray and/or by taking into account the
history of orthopedic intervention. A suspected new or an
exacerbation of an older fracture was determined from the
clinical symptoms and ﬁndings, such as acute back pain
(lumbago) and were conﬁrmed with a new comparative X-
ray.
A speciﬁc questionnaire on back pain evaluation was
completed at each patient’s visit, incorporating information
on frequency, severity of back pain, limitation of activities,
and days spent in the bed due to back pain in the previous
month.Thepatient’sperceivedseverityofbackpainwascap-
tured using a 100mm visual analogue scale (VAS), with 0
representing the absence of pain and 100 the worst possible
pain [16].
HRQoL was evaluated using the EQ-5D questionnaire
[17], which consists of 5 parameters (mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression).
Each of the above QoL dimensions had three levels (no
problem—some problems—extreme problems). Moreover,
patients expressed their perception of their QoL using a
scaled VAS (ranging from 0, the worst possible QoL, to
100, the best possible QoL—EQ-5D VAS). Spontaneously
reported adverse events were collected throughout the study.
3.StatisticalAnalysis
Descriptive statistics, such as frequencies, percentages,
means, standard deviations (SD), and ranges, were used to
describe the study population over time.
The number of fractures occurring in patients was sum-
marized in 6-month intervals (0–<6 months, and >6–12
months, >12–18 months). The regression models used to
analyze fracture rating for the total cohort are described else-
where [14]. In the Greek subpopulation, such an analysis is
not appropriate because of the small sample and thus is not
presented.
Back pain and QoL results were also analyzed over this
treatment period. The number and percentage of patients
with improvement, no change, or worsening in each domain
of the EQ-5D questionnaire were summarized at each visit
and the sign test was used to determine whether signiﬁcantly
more patients showed improvement than worsening. Back
pain changes from baseline in the VAS were analyzed using
a mixed model for repeated measures, adjusting for multiple
factors, as has been already reported [14]. EQ-5D HSV had a
continuous, nonparametric, bimodal distribution; therefore,
the Wilcoxon sign-rank test was used to assess changes from
baseline in this parameter.
Thenumberofpatientsreportingachangeintheseverity
and frequency of pain, the limitation of activities, and the
number of days in bed between baseline and a subsequent
visit, all recorded as improvement, worsening, or no change,
was also analyzed using the sign test. For the reference of
“days in bed,” there was no change if the diﬀerence reported
was ≤2d a y s .Journal of Osteoporosis 3
Table 1: Osteoporosis medications (other than teriparatide) prior and during the course of the study.
Medication Past use at baseline
(N = 301)
Ongoing at baseline
(N = 301)
3m o n t h s
(N = 297)a
6m o n t h s
(N = 282)a
12 months
(N = 280)a
18 months
(N = 278)a
Any medication 83.7% 74.0% 78.6% 79.0% 81.4% 76.9%
Any antiresorptives 81.7% 34.4% 6.8% 7.1% 7.9% 9.4%
Any bisphosphonates 38.0% 12.0% 0.7% 0.7% 1.8% 2.5%
Estrogen/progestin therapy 1.3% 0.0% 0.0% 0.0% 0.0% 0.0%
Estrogen therapy 1.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Raloxifene 7.0% 1.0% 1.0% 0.7% 0.4% 0.4%
Calcitonin 65.0% 21.4% 6.1% 6.0% 5.7% 6.5%
Calcium 68.0% 67.7% 75.6% 78.6% 81.1% 75.5%
Vitamin D 53.7% 62.5% 72.2% 74.0% 75.0% 70.8%
None reported 16.3% 26.0% 21.4% 21.0% 18.6% 23.1%
aStarted since previous observation.
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Figure 1: Back pain experienced.
4. Results
1648 patients were enrolled in the pan-European study in-
cluding 301 postmenopausal women from Greece. For the
Greek sample, mean age was 69.5 ± 8.5 years and mean BMI
was26.3±4.0. Baseline characteristics of the total cohort and
the Greek subpopulation of the EFOS study are presented
elsewhere [13, 15]. History of fracture after 40 years of age
wasreportedby92.5%ofpatients,withvertebralfracturebe-
ing the most prevalent (89.7%), while 39.5% of women had
2o rm o r ef r a c t u r e s .
The majority of women (83.7%) received prior antios-
teoporotic medication(s); the most common were calcitonin
(65.0%) and bisphosphonates (38.0%), most of which were
stopped during TPTD treatment. The use of calcium and
vitamin D was very frequent throughout the study (75.5%
and 70.8% at treatment conclusion, resp.) (Table 1).
4.1. Treatment Compliance and Safety. At 3, 6, 12, and 17
months, 94.7%, 92.6%, 88.3%, and 79.6% of patients, res-
pectively, were still receiving TPTD treatment. Interestingly
persistence with treatment fell to 36.5% in the last month of
treatment (as, at the time of the study, TPTD was approved
for an 18-month period).
Of those patients discontinuing treatment, only 5 (1.8%)
reported an adverse event and 2 (0.7%) died, while noncom-
pliance and patient decision accounted for 28 (10.1%)
and physcian decision for 7 (2.5%) discontinuations. Mean
TPTD treatment duration was 504 ± 158 days. After 18
months, 89 of 199 patients (44.7%) who were follow-
ed up reported some physical activity, compared with
79/291(27.1%) who were reported to exercise at baseline.
A detailed adverse event report was not available for the
Greekcohort;however,therateofdiscontinuationduetoad-
verse events is low. Safety results for the total EFOS group are
presented elsewhere [14].
4.2. Incidence of New Osteoporotic Fractures. The incidence
of new osteoporotic fractures during the ﬁrst 6-month
treatment periodwas402fracturesper10,000patient/years,
while there were 342 and 346 fractures per 10,000 patient/
years,respectively,inthesubsequent6-monthtreatmentper-
iods.
BMD was not evaluated as part of this study. Where col-
lected, BMD T-score in 18 months of treatment compared
with baseline was in the lumbar spine −2.54 ± 0.74 (N =
120) versus −3.46 ± 0.67 (N = 175) and the femoral neck
−2.40±0.75(N = 11)versus −3.07±0.58(N = 35).AsBMD
was not a study endpoint, no statistical analysis is provided.
4.3. Back Pain. When asked about back pain at baseline (be-
fore TPTD initiation), 93.2% of women reported having ex-
perienced back pain, while 39.9% reported back pain every
day or almost every day. The majority of patients (89.9%)
quantiﬁed back pain as moderate or severe. Moderate or se-
verelimitationofactivitieswasreportedby62.3%ofwomen.
The mean (SD) VAS value for patients’ perceived back pain
was 59.3 ±27.5mm.
Back pain reported by patients during the previous
month at each visit was reduced to 77.8% and 64.2% of pa-
tients, at 6 and 18 months of TPTD treatment, respectively
(Table 2 and Figure 1). Back pain every day or almost every
day was reported by 3.9% and 2.2% at the same time4 Journal of Osteoporosis
Table 2: Back pain reporting and qualiﬁcation in the study course.
% of Patients Baselineb 3m o n t h s c 6m o n t h s c 12 monthsc 18 monthsc
Reporting back pain (BP) 93.2% 84.6% 77.8% 66.4% 64.2%
BP every/almost every day 39.9% 7.5% 3.9% 2.5% 2.2%
Moderate or severe BP 89.9% 69.4% 50.7% 42.4% 32.4%
Moderate or severe
limitation of activities 62.3% 36.7% 24.0% 18.3% 14.8%
bDuring the last 12 months.
cDuring the last month.
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Figure 2: Percentage of patients with moderate or severe back pain/
limitation of activities.
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Figure 3: Back pain as deﬁned by patients through the visual anal-
ogue scale tool (mm) (mean, SD).
intervals, respectively. Moderate or severe back pain was re-
ported by 32.4% of women, while moderate or severe limita-
tion of activities was reported by 14.8% of patients at the
conclusionofthe18-monthTPTDtreatmentperiod(Table 2
and Figure 2). At that time, mean VAS value for back pain
was 19.3 ± 21.5( Figure 3).
There was a statistically signiﬁcant reduction in the
frequency of back pain relative to that experienced prior to
treatment, as well as a signiﬁcant improvement in the sever-
ity of back pain (moderate or severe back pain) and the
limitation of patients’ activities atthe end of the ﬁrst, second,
andthirdsemester(i.e.,6,12,and18months)ofTPTDtreat-
ment (P<0.001) (Table 3).
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Figure 4: EQ-5D: mobility.
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Figure 5: EQ-5D: usual activities.
4.4. Health-Related Quality of Life (HRQoL). Improvement
was identiﬁed in all dimensions (mobility, self-care, usual
activities, and pain/discomfort) of the EQ-5D questionnaire
(Figures 4, 5,a n d6). The mean (SD) value of the 100mm
VAS was 54 ± 25 prior to treatment initiation and 80 ± 19
at the conclusion of the 18-month TPTD treatment period
(P<0.001) (Figure 7). Median (Q1–Q3) EQ-5D HSV
improved from 0.516 (−0.016–0.725) at baseline to 0.848
(0.725–1.000)at18months(Wilcoxonranktest:P<0.001)).
Patients also evaluated their disposition at the end of
the treatment period: 45.8% reported an improvement in
anxiety/depression compared with baseline (P<0.001).Journal of Osteoporosis 5
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Figure 6: EQ-5D: pain/discomfort and anxiety/depression.
Table 3: % of patients experiencing improvements in frequency and severity of back pain and limitation of activities.
Improvement (% of patients) 3 months 6 months 12 months 18 months
Frequency of back pain 69.8%∗ 77.3%∗ 79.9%∗ 76.9%∗
Severity of back pain 54.3%∗ 65.4%∗ 69.8%∗ 71.6%∗
Limitation of activities 53.1%∗ 66.4%∗ 68.7%∗ 65.1%∗
∗Sign test, change from baseline, P<0.001.
∗Unadjusted sign change versus baseline (P<0.001)
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Figure 7: EQ-5D as deﬁned by patients through the visual analog
scale tool (mm) and EQ-5D VAS change from baseline (mm).
5. Discussion
EFOS, a 3-year prospective, noninterventional, multicenter
study evaluated the real-time use of TPTD as an antiosteo-
porotic treatment in postmenopausal women. In the overall
population of 1648 osteoporotic women in EFOS, a reduc-
tion (approx. 47%) in the incidence of any new osteoporotic
fractures (vertebral and nonvertebral) was observed between
the 1st (0 to 6 months) and 3rd (12 to 18 months) 6-month
periods of TPTD treatment.
National subanalyses are useful because local physicians
are interested to know whether results from international
studies can be applied to local populations. Where there are
adequate national data, they may strengthen the outcomes of
a multinational study. In the Greek subgroup, the incidence
of fractures per 10,000 patient years was 402 (n = 6, 2.0%)
in the 1st 6-month period versus 346 fractures per 10,000
patient years (n = 5, 1.7%) in the 3rd, which reﬂects the
total cohort. Because of the small numbers in the Greek
subgroup, statistical power to show reduction in fracture
rates was inadequate. However, the trend for a reduction in
fracture rates is in accordance with the 47% reduction after
12–18 months shown in the total population [14].
An improvement was observed in the frequency and
severity of back pain and the conduct of the patients’ usual
activities due to back pain. Additionally, there was a signif-
icant improvement in all examined parameters related to
Q o La sw e l la sap o s i t i v ee ﬀect in self-reported anxiety/
depression. The relationship between the frequency of new
osteoporotic fractures and QoL of patients sustaining these6 Journal of Osteoporosis
fractures has been demonstrated in several studies [18–22].
Women with a poor response to antiosteoporotic treatment
and a greater number of osteoporotic fractures had in
parallel a diminished HRQoL [22, 23]. The reduction in
the frequency and severity of back pain following the 18-
month TPTD treatment observed in the Greek cohort,
may be associated with the signiﬁcant improvement in
the patient HRQoL and the improvement in mobility and
usual activities. Similar reductions in back pain and an
improvement in reported QoL versus patients receiving
placebo or comparator medication have been recorded in
other studies and meta-analyses [24–28].
Osteoporosis,evenwithoutfractures,hasbeenassociated
with the undesirable consequences of chronic pain, impaired
physical ability, reduced social activity, poor well-being and
depressed mood, which overall lead to a reduced quality
of life [20, 29]. Depression has been associated with low
bone mineral density [30, 31]a n dm a yh a v ea na d v e r s e
impact on osteoporosis, despite methodological weaknesses
of studies suggesting this preclude deﬁnitive conclusions
[32]. The MORE study has shown increase of prevalence
of depression among patients with osteoporosis where, in
fact, postmenopausal women with vertebral fractures had
greater prevalence of depressive symptoms and probable
depression than those without fractures, and the number
of fractures was proportional to an aggravated “Geriatric
Depression Scale” score [33]. In the literature, the eﬀect
of depression or its medication on osteoporosis and bone
density is more often addressed. In contrast, the eﬀect of
osteoporosis or its comorbidities (like back pain) on a pa-
tient’s psychosocial condition (i.e., a combination of the
patient’s psychological status and the limitations on a social
level caused by the disease) and the improvement that osteo-
porosistreatmentmayoﬀerneedstobefurtherin-vestigated.
It may be hypothesized that the improvements in pain and
movement limitations in our patients explain the concurrent
improvement in moods.
In chronic diseases like osteoporosis, patient compliance
with the administration of a medication is necessary for
treatment eﬀectiveness [34, 35]. Despite the daily routine
parenteral administration of TPTD, patient compliance with
treatmentintheGreekcohortremainedataremarkablyhigh
level, dropping only after 17 months (when 18 cartridges
had been used). Similar levels of treatment compliance in
TPTD therapy were reported in other recent studies in
Europe [36, 37] and Canada [38]. On the contrary, patient
adherence after 1 or 2 years of treatment with an oral
antiresorptive does not exceed 50% [39–42]. Moreover, the
majority of patients (83.1%) had previously sustained an
osteoporotic fracture, despite previous administration of an
antiosteoporotic medication. Disappointing results with the
previous medication combined with the patients’ aggravated
condition outweigh the potential concerns of the daily ad-
ministration of an injectable medication.
Discontinuation of TPTD treatment was low (13.6%)
due mainly to patient (9.0%) or physician (2.5%) decision
and less to adverse events (1.8%). This high rate of treat-
ment completers might be interpreted in the context of im-
provement in back pain and QoL, observed from the ﬁrst
quar-ter of TPTD treatment in this study. The high num-
ber of dropouts at the 18th month of treatment compared
with the 17th (62.4% versus 22%) may be attributed to
the fact that 18-month treatment is equal to 19 cartridges of
medication prescribed (many physicians believed that they
should give 18 prescriptions and thus patients completed
their TPTD treatment prematurely).
Patient selection in multicenter phase III clinical studies
is subject to many exclusion criteria [10–12, 24, 43]. In nor-
mal clinical practice, however, patients initiating a treatment
do not necessarily demonstrate the same characteristics as
those enrolled in preregistration trials. They may display
multiple comorbidities or might be receiving nonevaluated
concomitant medications, which would exclude them from
preregistration trials. This renders observational studies an
essential tool for physicians to evaluate any treatment in a
naturalistic setting.
EFOS as a noncontrolled, noninterventional, observa-
tional study has a number of limitations. Firstly, the study
is not designed to evaluate the cause and eﬃcacy of TPTD
but to complement randomized controlled trials to provide
data on outcomes of patients treated with TPTD in normal
clinical practice.
The results are speciﬁc to postmenopausal women with
severe osteoporosis and may not be applicable to other pa-
tients receiving TPTD. Second, we did not determine mor-
p h o m e t r i cv e r t e b r a lf r a c t u r e sa sX - r a y sw e r eo n l yp e r f o r m e d
in symptomatic patients, so we may have underestimated the
eﬀectiveness in overall risk of vertebral fracture. Third, we
did not gather data on the use of analgesics during the study.
Patient compliance and continuation of treatment was
assessedbyquestioningthepatientandnotveriﬁedbycollec-
tion of unused medication. The high compliance may also
have been encouraged by participation in the study.
Lastly, the tolerance and safety of TPTD was not one of
the study objectives. Adverse events were recorded according
to the standard Adverse Event Reporting procedure and are
reported elsewhere for the total study.
In conclusion, as identiﬁed in the overall European EFOS
population, the results of 18-month TPTD treatment in
Greekosteoporoticwomenincommonclinicalpractice,with
comorbidities and concomitant medications indicate a sig-
niﬁcant improvement in back pain and HR QoL.
The HellenicEFOS StudyGroup
This group includes the following members Alexiou P, Bou-
kis M, Dimopoulos N, Dreatakis K, Farchat J, Giota A, Theo-
dorakopoulos P, Kakavouli G, Karambatsas D, Karras D,
Kaskani E, Kefallinou M, Kosmidis C, Lagoudakis A, Lasi-
thiotakis I, Lazaridis G, Maidanoglou P, Makiev G, Maltas N,
Mantzilas T, Matsouka A, Notaras I, Papakitsou E, Rambidis
I, Repousis P, Saddik G, Sideridis A, Stamatiadou A, Trovas
G, and Xirogiannis G.
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